Advanced Biomed Inc. Announces 1 for 20 Share Consolidation
Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary
Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering
IPO Update: Advanced Biomed Finalizes $112 Million U.S. IPO Plan
Advanced Biomed sets IPO terms, which could value the biotech at up to $625 million
Advanced Biomed Begins $150 Million U.S. IPO Rollout
Advanced Biomed to raise $150M in IPO